Streetbeat News

Analyst Ratings

TECH

Stifel analyst Daniel Arias maintains a Buy rating on Bio-Techne (NASDAQ:TECH) but has lowered the price target from $104 to $65.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 6:43 pm

MSFT

Stifel analyst Brad R. Reback reiterated a Buy rating on Microsoft Corp (NASDAQ:MSFT) with a price target of $390. The analyst highlighted Microsoft's potential to leverage its AI leadership position to accelerate share gains across its platforms. This is the first time in over two decades that Microsoft is not playing from behind in an emerging tech trend. The analyst expects the coming AI cycle to allow Microsoft to sustain double-digit revenue and profitability growth for years to come.

Portfolio Pulse from Anusuya Lahiri

November 01, 2023 | 6:40 pm

F

GM

Barclays analyst Dan Levy has upgraded the rating on Ford Motor Company (NYSE:F) and General Motors Company (NYSE:GM) from Equal-Weight to Overweight with a price target of $14 and $37, respectively. The analyst notes that despite structural concerns, a modest reversal of negative sentiment could drive an attractive upside. The analyst prefers GM over Ford, noting that sentiment on GM is considerably worse, which should offer an easier reversion.

Portfolio Pulse from Shivani Kumaresan

November 01, 2023 | 6:38 pm

AGCO

Stifel analyst Stanley Elliott maintains a Buy rating on AGCO (NYSE:AGCO) but lowers the price target from $161 to $160.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 6:36 pm

MCK

A significant bearish stance has been taken on McKesson (NYSE:MCK) by a large investor, as observed in the unusual options activity. The sentiment among these big-money traders is 20% bullish and 80% bearish. The whales have been targeting a price range from $445.0 to $480.0 for McKesson over the last 3 months. The current price of MCK is up 1.34% at $461.45. Argus Research maintains their Buy rating on McKesson with a price target of $480.

Portfolio Pulse from Benzinga Insights

November 01, 2023 | 6:31 pm

TGT

A significant amount of unusual options activity has been detected for Target Corporation (NYSE:TGT), with a mix of bullish and bearish stances. The trades range from $80.0 to $135.0 for Target over the last 3 months. The current price of TGT is down -1.45% at $109.18. Analysts from B of A Securities, Tigress Financial, Truist Securities, and Evercore ISI Group have given their ratings and price targets for the stock.

Portfolio Pulse from Benzinga Insights

November 01, 2023 | 6:31 pm

DHR

Benzinga's options scanner detected over 13 options trades for Danaher (NYSE:DHR) totaling $345,933. Whales have been targeting a price range from $145.0 to $190.0 for Danaher over the last 3 months. The price of DHR is down -1.55% at $189.04. Major financial institutions maintain positive ratings on Danaher with price targets ranging from $215 to $260.

Portfolio Pulse from Benzinga Insights

November 01, 2023 | 6:31 pm

SLAB

Barclays analyst Blayne Curtis has upgraded Silicon Laboratories (NASDAQ:SLAB) from Underweight to Equal-Weight.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 6:30 pm

PFE

Pfizer Inc reported a loss for Q3 with a 42% slump in sales to $13.23 billion, down from $22.64 billion a year ago. Despite this, the company beat the consensus of $12.72 billion. Following the earnings announcement, Morgan Stanley and Barclays lowered their price targets on Pfizer.

Portfolio Pulse from Lisa Levin

November 01, 2023 | 6:29 pm

ARGX

Truist Securities analyst Joon Lee has reiterated a 'Buy' rating on argenx (NASDAQ:ARGX) and maintained a price target of $570.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 6:25 pm